東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Molecules engineered against oncogen...

Corey, E. J.

FindBook

Google Book

Amazon

博客來

Molecules engineered against oncogenic proteins and cancer /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Molecules engineered against oncogenic proteins and cancer // E.J. Corey, Yong-Jin Wu.
其他題名:	Molecules engineered against oncogenic proteins and cancer : discovery, design, and development
作者:	Corey, E. J.
其他作者:	Wu, Yong-Jin.
出版者:	Hoboken, New Jersey :John Wiley & Sons, Inc., : c2024.,
面頁冊數:	viii, 381 p. :col. ill. ;29 cm.
標題:	Protein-tyrosine kinase - Inhibitors -
ISBN:	9781394207084

Molecules engineered against oncogenic proteins and cancer /
Corey, E. J.

Molecules engineered against oncogenic proteins and cancer /Molecules engineered against oncogenic proteins and cancer : discovery, design, and developmentE.J. Corey, Yong-Jin Wu. - Hoboken, New Jersey :John Wiley & Sons, Inc.,c2024. - viii, 381 p. :col. ill. ;29 cm.

Includes bibliographical references and index.

Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine's most challenging areas - cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. Molecules Engineered Against Oncogenic Proteins and Cancer includes information on: Each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action; Mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent; History of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer; and The discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field.

ISBN: 9781394207084US175.00Subjects--Topical Terms:

770827
Protein-tyrosine kinase
--Inhibitors

LC Class. No.: RC271.P76 / C67 2024

Dewey Class. No.: 616.99/4061

Molecules engineered against oncogenic proteins and cancer /
LDR:02097cam a2200229 a 4500 001 2367334
008 241125s2024 njua b 001 0 eng d
020 $a 9781394207084 $q (hbk.) : $c US175.00
020 $a 1394207085 $q (hbk.)
020 $z 1394207093 $q (ebk.)
020 $z 1394207107 $q (ebk.)
020 $z 9781394207091 $q (ebk.)
020 $z 9781394207107 $q (ebk.)
035 $a (OCoLC)1393306594 $z (OCoLC)1393345170 $z (OCoLC)1393360227
040 $a EBLCP $b eng $e aacr2 $c EBLCP $d YDX $d OCLCQ $d YDX $d DG1 $d N$T $d OCLCO $d WSU $d XII $d OCLCO
050 # 4 $a RC271.P76 $b C67 2024
082 0 4 $a 616.99/4061 $2 23/eng/20230921
100 1 $a Corey, E. J. $3 813960
245 1 0 $a Molecules engineered against oncogenic proteins and cancer / $c E.J. Corey, Yong-Jin Wu.
246 3 4 $a Molecules engineered against oncogenic proteins and cancer : discovery, design, and development
260 # $a Hoboken, New Jersey : $b John Wiley & Sons, Inc., $c c2024.
300 $a viii, 381 p. : $b col. ill. ; $c 29 cm.
504 $a Includes bibliographical references and index.
520 # $a Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine's most challenging areas - cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented. Molecules Engineered Against Oncogenic Proteins and Cancer includes information on: Each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action; Mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent; History of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer; and The discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field.
650 # 0 $a Protein-tyrosine kinase $x Inhibitors $x Therapeutic use. $3 770827
650 # 0 $a Carcinogenesis $x Molecular aspects. $3 1084446
650 # 0 $a Cancer $x Treatment. $3 618125
700 1 # $a Wu, Yong-Jin. $3 3729105